KRAS and non-small cell lung carcinoma: To further understand the underlying mechanisms, we performed transcriptomic analysis of 4 KRAS-mutant NSCLC cell lines (A549, Calu1, H460 and H23) treated with trametinib at several time points (Supplementary Fig. 1b, c).